Antiretroviral (ARV) Agents Market

Antiretroviral (ARV) Agents Market Forecast and CAGR

The Antiretroviral (ARV) market is in considerable demand as the current situation of the pandemic has constructed such an environment, where new medicines and vaccines should be manufactured according to the size of the population, thus expected to grow at a significant rate from 2021 to 2030. The prognosis of people suffering from HIV has been improved with the help of antiretroviral agents.

The rate of HIV infected people has been on top as large set of people is known of the infection after it has been diagnosed. These are basically combination drugs that’s help immune system to react to the mechanism and not resist it. The market is set to reach heights in the given forecast period 2021-2031.

What is Driving Demand for Antiretroviral (ARV) Agents Market?

Increase in the number of chronic diseases, HIV infections will lead to more medicinal development. The surge for anti-resistant medicines has been in demand.  In addition as monoclonal antibodies demand increases, the growth for the antiretroviral (ARV) agents market will spike its rate, demand in personalized medicines has increased bio production, accelerating antiretroviral (ARV) demand.

The rising funding from private & government organizations for the development of vaccine, increase in development in the pharmaceutical and biotechnology industry, and surge in demand for antiretroviral agents are boosting the market. Furthermore, the rising innovation and new technological advancement is driving the demand for antiretroviral (ARV).

As the prevalence rate increases in HIV diseases, the initiatives from the pharmaceuticals, the government, the manufacturers have been rising at a steady growth.

U.S. Antiretroviral (ARV) Agents Market Outlook

U.S. is considered to be the most influencing regions in the global antiretroviral (ARV) agents market due to the existence of prime biopharmaceutical manufacturing companies. The economic development and the infrastructure development has been a major part in revenue spike.

Furthermore, the rising prevalence of various chronic disorders are likely to augment the growth of the antiretroviral (ARV) agents market in the region. Due to the current pandemic, government is funding the biomedical industries to spur the development of antiretroviral (ARV). 

According to CDC, in 2019, U.S. reported on an average of 1,189,700 million people of 13 years of age and above suffered from HIV infection, amongst them almost 13% are unaware of the HIV infection. In 2020, ViiV Healthcare announced US FDA approval for its Rukobia (fostemsavir), 600 mg extended-release tablets.

The increase in the human immunodeficiency Virus prevalence has created awareness amongst the population. This has led government to focus on healthcare infrastructure and diagnostics to bring in health and life.

Europe Antiretroviral (ARV) Agents Market Outlook

The presence of key players and rising product launches and approvals in the region is expected to boost the demand for antiretroviral (ARV) agents. Furthermore, the R&D is focusing into new technological advancements which is going to lead the antiretroviral (ARV) production market to reach heights.

U.K. has been known to expand the market in the given forecast period in 2020, Theratechnologies Europe Limited, collaborated with Loxxess for distribution of TROGARZO, an ART in Europe region. The increase in prevention of the disease has made the market to rise significantly.

Key manufactures and suppliers

• ViiV Healthcare
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Merck Sharp & Dohme Corp.
• Bristol-Myers Squibb Company
• Janssen Pharmaceuticals, Inc.
• Pfizer
• Boehringer Ingelheim International GmbH
• AbbVie Inc.
• Genentech, Inc.
• Mylan N.V.
• Other

Antiretroviral (ARV) Agents Market Report Highlights:

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

Key segments

• By Drug Type

  • Nucleoside Reverse Transcriptase Inhibitors
  • Multi-Class Combination Products
  • Protease Inhibitors
  • HIV Integrase Strand Transfer Inhibitors
  • Non-Nucleoside Reverse Transcriptase Inhibitors
  • Entry Inhibitors — CCR5 Co-Receptor Antagonist
  • Fusion Inhibitors and Others

• By Distribution channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

• By Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

 The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

NOTE: Although care has been taken to maintain the highest levels of accuracy in reports, recent market/vendor-specific changes may time to reflect in the analysis.